Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct 1;272(10):669.
doi: 10.1007/s00415-025-13418-0.

Data-driven subtypes of subjective cognitive decline: neuropsychological profiles, Alzheimer's disease biomarkers, and clinical trajectories

Affiliations

Data-driven subtypes of subjective cognitive decline: neuropsychological profiles, Alzheimer's disease biomarkers, and clinical trajectories

Salvatore Mazzeo et al. J Neurol. .

Abstract

Objectives: Subjective Cognitive Decline (SCD) is a heterogeneous condition recognized as the earliest manifestation of Alzheimer's disease (AD). We hypothesized that the heterogeneity of SCD may be synthesized in distinct subtypes.

Methods: We analyzed data from the AD Neuroimaging Initiative (ADNI) database. For all participants, demographic variables, cognitive measures, APOE genotype, CSF biomarkers, brain MRI, and FDG-PET data were available. Participants underwent follow-up visits every 6 or 12 months.

Results: 542 cognitively normal (CN), 346 SCD, and 423 early mild cognitive impairment (E-MCI) individuals were included. A data-driven approach based on cognitive measures identified three SCD clusters (k1, k2, k3) that performed differently in verbal memory (k2 outperformed all the groups and k3 showed the poorest performance, p < 0.001) and in executive function (k1 had the lowest scores, p = 0.006). Regarding CSF biomarkers, k2 exhibited lower p-tau (20.6 ± 9.2 vs. 24.2 ± 13.6, p = 0.03) and k3 had higher Aβ42 levels (1131.3 ± 379.8 vs. 942.87 ± 355.3, p = 0.01) compared to the E-MCI group, while there were no differences between k1 and E-MCI. Regarding brain FDG-PET, k1 demonstrated reduced uptake compared to CN, k2, and k3 (p < 0.001). During follow-up, k1 exhibited a higher rate of progression to MCI or dementia compared to k2 and k3 (Log-rank χ2 = 18.18, p = 0.0002) and a steeper decline in general cognition and long-term verbal memory compared to k2.

Interpretation: We proposed a three-subgroup system classification for SCD, reflecting different cognitive profiles and longitudinal trajectories. Classifying individuals with SCD may enhance diagnostic pathways and inform personalized interventions.

Keywords: Alzheimer’s disease; Mild cognitive impairment; Neuropsychology; Subjective cognitive decline.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflicts of interest: The authors declare that they have no competing interests in relation to this work. Massimo Filippi is Editor-in-Chief of the Journal of Neurology. Federica Agosta is member of the Editorial Board of the Journal of Neurology.

References

    1. Jessen F, Amariglio RE, van Boxtel M et al (2014) A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement 10:844–852. https://doi.org/10.1016/j.jalz.2014.01.001 - DOI - PubMed
    1. Ma S-J, Yu Y-X, Tian K et al (2024) Prevalence and risk factors of subjective cognitive decline in older adults in Baotou, China: a cross-sectional study. Front Aging Neurosci. https://doi.org/10.3389/fnagi.2024.1422258 - DOI - PubMed - PMC
    1. Jack CR, Bennett DA, Blennow K et al (2018) NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement 14:535–562. https://doi.org/10.1016/j.jalz.2018.02.018 - DOI - PubMed
    1. Parfenov VA, Zakharov VV, Kabaeva AR, Vakhnina NV (2020) Subjective cognitive decline as a predictor of future cognitive decline: a systematic review. Dement Neuropsychol 14:248–257. https://doi.org/10.1590/1980-57642020dn14-030007 - DOI - PubMed - PMC
    1. Cummings JL, Zhou Y, Lee G et al (2025) Alzheimer’s disease drug development pipeline: 2025. Alzheimer’s & Dementia: Translational Research & Clinical Interventions 11:e70098. https://doi.org/10.1002/trc2.70098 - DOI

MeSH terms

LinkOut - more resources